Premium
Modulation of Growth of Melanoma
Author(s) -
Pucci M.,
Lotti T.,
Tuci F.,
Brunetti L.,
Rindi L.,
Fibbi G.,
Pasquali F.,
Chiaruci V. P.
Publication year - 1988
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1988.tb04922.x
Subject(s) - cortisone , medicine , cortisone acetate , heparin , melanoma , plasminogen activator , microgram , fibrin , endocrinology , immunology , cancer research , biology , biochemistry , in vitro
Combined heparin‐cortisone treatment induces regression of growth in a variety of marine tumors including menaoma. We injected 92 inbred C 57 bl/6 male mice each with 5 × 10 5 melanoma cells (876, 876 F1, and 876 A6 lines) with different metastatic potential. Heparin (400 U/ml) and cortisone acetate (250 mg/kg SC injections) were given daily. Control experiments were performed both with the administration of no drugs and with administration of cortisone alone. Plasminogen activator activity, which is notoriously related to tumor growth, was evaluated using fibrin plate technique in TO fragments taken before and 20 days after the combined heparin‐cortisone treatment of 876 F1 and B16 A6 melanomas. The combined heparin‐cortisone treatment slowed tumor growth, but no tumour regression was observed. Cutaneous fibrinolytic activity appeared increased in all specimens after the treatment.